JP2023527542A - コレステロール関連障害を治療するためのｐｃｓｋ９阻害剤及びその使用の方法 - Google Patents
コレステロール関連障害を治療するためのｐｃｓｋ９阻害剤及びその使用の方法 Download PDFInfo
- Publication number
- JP2023527542A JP2023527542A JP2022573247A JP2022573247A JP2023527542A JP 2023527542 A JP2023527542 A JP 2023527542A JP 2022573247 A JP2022573247 A JP 2022573247A JP 2022573247 A JP2022573247 A JP 2022573247A JP 2023527542 A JP2023527542 A JP 2023527542A
- Authority
- JP
- Japan
- Prior art keywords
- ldl
- subject
- pcsk9
- hefh
- pediatric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063032451P | 2020-05-29 | 2020-05-29 | |
| US63/032,451 | 2020-05-29 | ||
| PCT/US2021/034489 WO2021243002A1 (en) | 2020-05-29 | 2021-05-27 | Pcsk9 inhibitors and methods of use thereof to treat cholesterol-related disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023527542A true JP2023527542A (ja) | 2023-06-29 |
| JPWO2021243002A5 JPWO2021243002A5 (https=) | 2024-06-03 |
| JP2023527542A5 JP2023527542A5 (https=) | 2024-06-03 |
Family
ID=78722769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022573247A Pending JP2023527542A (ja) | 2020-05-29 | 2021-05-27 | コレステロール関連障害を治療するためのｐｃｓｋ９阻害剤及びその使用の方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230235085A1 (https=) |
| EP (1) | EP4157887A4 (https=) |
| JP (1) | JP2023527542A (https=) |
| CN (1) | CN115916838A (https=) |
| AR (1) | AR122180A1 (https=) |
| AU (1) | AU2021281256A1 (https=) |
| CA (1) | CA3179316A1 (https=) |
| IL (1) | IL298375A (https=) |
| JO (1) | JOP20220322A1 (https=) |
| TW (1) | TW202210524A (https=) |
| WO (1) | WO2021243002A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20200043A1 (ar) | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| AU2020209216A1 (en) | 2019-01-18 | 2021-08-26 | Astrazeneca Ab | PCSK9 inhibitors and methods of use thereof |
| SG11202107614PA (en) | 2019-01-18 | 2021-08-30 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof |
| CN121693519A (zh) | 2023-08-14 | 2026-03-17 | 信立泰(成都)生物技术有限公司 | Pcsk9抑制剂用于治疗或预防胆固醇相关疾病的方法 |
| WO2025265012A1 (en) * | 2024-06-21 | 2025-12-26 | Amgen Inc. | Compositions comprising anti-pcsk9 antbodies |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009033743A1 (en) * | 2007-09-13 | 2009-03-19 | University Of Zurich Prorektorat Forschung | Monoclonal amyloid beta (abeta)-specific antibody and uses thereof |
| EP2706070A1 (en) * | 2012-09-06 | 2014-03-12 | Sanofi | Combination treatments involving antibodies to human PCSK9 |
| PL3169353T3 (pl) * | 2014-07-16 | 2020-06-01 | Sanofi Biotechnology | SPOSOBY LECZENIA PACJENTÓW Z HETEROZYGOTYCZNĄ HIPERCHOLESTEROLEMIĄ RODZINNĄ (heFH) |
-
2021
- 2021-05-27 CA CA3179316A patent/CA3179316A1/en active Pending
- 2021-05-27 CN CN202180039317.4A patent/CN115916838A/zh active Pending
- 2021-05-27 AR ARP210101427A patent/AR122180A1/es unknown
- 2021-05-27 JP JP2022573247A patent/JP2023527542A/ja active Pending
- 2021-05-27 WO PCT/US2021/034489 patent/WO2021243002A1/en not_active Ceased
- 2021-05-27 IL IL298375A patent/IL298375A/en unknown
- 2021-05-27 EP EP21812361.0A patent/EP4157887A4/en active Pending
- 2021-05-27 US US17/999,373 patent/US20230235085A1/en active Pending
- 2021-05-27 AU AU2021281256A patent/AU2021281256A1/en active Pending
- 2021-05-28 TW TW110119435A patent/TW202210524A/zh unknown
-
2022
- 2022-11-27 JO JOJO/P/2022/0322A patent/JOP20220322A1/ar unknown
Non-Patent Citations (3)
| Title |
|---|
| JACC, vol. 75, no. 6, JPN6025021741, 18 February 2020 (2020-02-18), pages 565 - 574, ISSN: 0005834006 * |
| JOURNAL OF CLINICAL LIPIDOLOGY, vol. 14, JPN6025021742, 28 March 2020 (2020-03-28), pages 322 - 330, ISSN: 0005834007 * |
| NEJM, vol. 383, no. 14, JPN6025021743, 1 October 2020 (2020-10-01), pages 1317 - 1327, ISSN: 0005609058 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021243002A1 (en) | 2021-12-02 |
| IL298375A (en) | 2023-01-01 |
| TW202210524A (zh) | 2022-03-16 |
| CA3179316A1 (en) | 2021-12-02 |
| AU2021281256A1 (en) | 2022-12-22 |
| EP4157887A1 (en) | 2023-04-05 |
| US20230235085A1 (en) | 2023-07-27 |
| CN115916838A (zh) | 2023-04-04 |
| JOP20220322A1 (ar) | 2022-11-27 |
| AR122180A1 (es) | 2022-08-24 |
| EP4157887A4 (en) | 2024-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12331122B2 (en) | Anti-ASGR-1 monoclonal inhibitory antibodies | |
| EP2074149B1 (en) | Compositions and methods relating to glucagon receptor antibodies | |
| JP7194104B2 (ja) | 抗ｔｌ１ａモノクローナル抗体の中和 | |
| JP2023527542A (ja) | コレステロール関連障害を治療するためのｐｃｓｋ９阻害剤及びその使用の方法 | |
| JP2025105701A (ja) | 組換えポリクローナルタンパク質およびその使用方法 | |
| JP7558949B2 (ja) | 抗ｃｔｌａ－４結合タンパク質およびその使用方法 | |
| KR20220004985A (ko) | Cd40 활성화 특성을 가진 재조합 단백질 | |
| US20220064268A1 (en) | Recombinant polyclonal proteins targeting zika and methods of use thereof | |
| US20220041715A1 (en) | Recombinant polyclonal proteins targeting covid-19 and methods of use thereof | |
| US20230265192A1 (en) | Anti-ctla-4 binding proteins and methods of use thereof | |
| CA2779683A1 (en) | Anti-c-mpl antibodies | |
| WO2020140070A1 (en) | Anti-b7-h4 binding proteins and methods of use thereof | |
| HK40090853A (zh) | Pcsk9抑制剂及其用於治疗胆固醇相关障碍的方法 | |
| US20250289903A1 (en) | Methods and compositions for treating eosinophil driven diseases and disorders | |
| TW202323300A (zh) | 抗tigit構築體及其用途 | |
| TW202228768A (zh) | 用於治療疼痛之化合物及方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240524 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240524 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20250526 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250603 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20250828 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251203 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20260407 |